about
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic StudyUse of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patientsHCV epidemiology in high-risk groups and the risk of reinfection.Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain.Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatmentIFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansPrediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexesLow Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.[Prevalence of serum antibodies against Bartonella ssp. in a health population from the south area of the Seville province]Host genetics.Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.Non-Alcoholic Fatty Liver Disease in HIV Infection.Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients.Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients.High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis.HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients.Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals.Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease.HAART and the liver: friend or foe?
P50
Q28552246-96DB6BBE-3E0C-4274-ACF9-90A1FEA88586Q28764754-1DB23918-8900-47AE-9A45-08C250B92ABAQ30245241-46800BCF-0146-42EF-B3A1-F8A314A32F6AQ31114657-5C227E98-F8A8-4C12-BB1D-AE3F9A158D80Q33423922-7F60E156-32BF-41DD-816A-6D94BE7500A3Q33680935-0C87AA52-9DE9-4159-BC30-C9244435AC6EQ34852032-01604DF5-B951-418D-AC6B-513723B08E2EQ35036061-49FF246B-1194-428A-86CE-626108E415FBQ35153222-93446531-1455-4BFB-AEA1-66BED9E83112Q35760270-011362B4-6D89-44FC-BA55-0A08C514DEAEQ35862004-983E3A28-5C8E-4366-A877-1D06E1B9D482Q35862847-8628C675-42B4-455F-8CC7-EBE8FF08CAE3Q36054272-4372539E-5EA6-4A34-A75F-0BDBF485A547Q36135182-8062C5E1-A6E6-4381-8730-42B1E05F108DQ36223683-2525DCE2-4BF9-4AC2-9456-34B811F63DC7Q37863263-AEDE3E81-6DB9-4F84-B804-D73BBF7733E8Q37932339-4CE766A0-4500-42AB-B32D-19476FF45B12Q38236179-0D27B80F-D1E1-40AD-9A8F-B252E6EB5704Q38969617-49746821-E32B-453B-AFE3-8DF3BD454EF3Q39643290-FD6BD64F-FDE1-4E13-A07E-75530F7764B2Q39877513-6FCFCF68-22DF-42AB-B9D5-BF79827B14BFQ40043067-00E28143-E067-4D59-8071-2A93AB0A9832Q40092302-36FA5E4D-B5F0-4C3D-B7ED-C00F4756A4EDQ40137776-00FD0B51-CA6E-488C-874B-3EF29D5CA0E4Q40352938-B94C4AA0-9059-442F-86EF-C7D508B37CA3Q40360505-C9704DEB-392E-473D-A8A4-1AF5A2AF998EQ40399465-A74A38A0-3799-424E-A0E5-3D9F1D832D64Q40437474-6AC9362F-2B37-4ECF-B901-B749BC34A4A9Q40439142-1B490331-A126-48F8-83AB-DBEE8FCEAA66Q40486607-AD023117-D377-41DF-8E66-812990C7AC57Q40493714-58042F52-41C2-4298-AEC7-AE176E1552A9Q40653324-C495D01C-3085-4ED1-A25C-5C0E5BB1B5AEQ40998744-5F553F1D-2260-49C9-99DE-0C9AC2633003Q41008656-C7854D98-0F80-4F61-A52A-8D8747C224B3Q41089110-0ED20919-3362-467F-BED7-5E7C6E2FC5F3Q41117767-092F81B8-797C-4530-84D7-920D7B1F350DQ41556124-3ACFA33D-8070-4E8F-873C-0B8190DC8D5CQ41578791-BFF4B09F-7A76-45D4-8101-C2528CDCC02AQ41586032-9086E0A8-9663-4375-8211-ACBA331D1513Q41991102-2DCAAEBF-DFD8-469C-B9DE-8C2DF044D1AF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan Macías
@ast
Juan Macías
@en
Juan Macías
@es
Juan Macías
@nl
Juan Macías
@sl
type
label
Juan Macías
@ast
Juan Macías
@en
Juan Macías
@es
Juan Macías
@nl
Juan Macías
@sl
prefLabel
Juan Macías
@ast
Juan Macías
@en
Juan Macías
@es
Juan Macías
@nl
Juan Macías
@sl
P106
P1153
7007084201
P21
P31
P496
0000-0002-4778-790X